Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Varmx B.V.
BioCentury | Nov 14, 2024
Management Tracks
New CEOs at Valo, Apriori
Plus: Glasspool to lead VarmX, Novartis vet Eissa joins Cellares and updates from Mestag, Andera, Incyclix and more
BioCentury | Oct 13, 2023
Management Tracks
CSO Lawson succeeding CEO Öhrström at VarmX
Plus: New CMO at Glycomine and updates from Halo, Roth, Sound Bioventures and the Global Virus Network
BioCentury | May 26, 2023
Finance
May 25 Quick Takes: VarmX is latest biotech to extend series B
Plus: Apellis/Sobi candidate misses in ALS and updates from Annexon, Pfizer and more
BioCentury | Mar 9, 2023
Management Tracks
Biogen taps Dorsa to succeed Papadopoulos as chair
Plus: new chair at Venatorx, and updates from VarmX and Nutcracker
BioCentury | Jun 15, 2021
Emerging Company Profile
VectorY: Forbion’s next-generation gene therapy play
Emerging Company Profile: With €31M, VectorY builds a toolbox to develop, manufacture vectorized antibodies
BioCentury | May 26, 2021
Finance
Ysios goes all in on therapeutics with largest-ever €216M life sciences fund
Spanish firm bumps up commitment to drug developers
BioCentury | Jul 8, 2020
Finance
VarmX attracts investor syndicate with financial reserves to support coagulation company beyond €32M series B
Items per page:
1 - 10 of 12